Remove Cannabinoids Remove Clinical Trials Remove Collective
article thumbnail

Cannabinoids for Tinnitus?

Project CBD

While animal studies have revealed that cannabinoid receptors likely have a role in modulating auditory signaling, there is no compelling data either from animal or human studies for the use of cannabinoids to alleviate tinnitus.” There could be a role for cannabinoids in the management of tinnitus through their anticonvulsant effects.

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Could CBN really help you sleep? Consumer study data suggest yes.

The Cannigma

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Over 31 days, 388 people reported on their sleep before and after trialing the CBN product.

Sleep 133
article thumbnail

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

article thumbnail

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

article thumbnail

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. from 2020 to 2030 and generate revenue of $151.7

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.